Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...

Changes in Opioid Use Outcomes After Passage of Medical Marijuana Laws Jan. 13, 2025 — A new study found no changes in opioid outcomes among the general population with the states' passage of ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

As one of the world’s foremost medical universities, KI accounts for the single largest share of all academic medical research conducted in Sweden. KI also offers the country’s broadest range of ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

The Greater Middle East is home to a rich genetic diversity that remains largely untapped in genomic research. This Perspective explores its potential for rare disease research, obstacles limiting ...